Date: 2017-12-21
Type of information: Services contract
Compound: LISA TRACKER® kits for the monitoring of Remicade®
Company: Theradiag (France) MSD France (France)
Therapeutic area: Autoimmune diseases – Inflammatory diseases - Rheumatic diseases - Dermatological diseases - Digestive diseases
Type agreement: services contract
Action mechanism: theranostic test
Disease:
Details:
- • On December 21, 2017, Theradiag announced that it had signed a partnership with MSD France (Merck Sharp & Dohme) to supply its LISA TRACKER® kits for the monitoring of Remicade®. Under this agreement, MSD France has referenced the LISA TRACKER® monitoring kits to accompany the supply of Remicade®. Kits will be supplied under the conditions set out in the contracts to supply Remicade® won by MSD France.
- Theradiag will also be responsible for implementation, training in the use of the kits by laboratories and follow-up on monitoring-related requests from clinicians.
Financial terms:
Latest news:
Is general: Yes